WEBULL
WebtradeDownload

MoonLake Immunotherapeutics (MLTX) Reports Wider Net Loss, Is It Still Below Fair Value?

Simply Wall St · 2d ago

MoonLake Immunotherapeutics (MLTX) has drawn fresh attention after reporting third quarter and nine month 2026 results, with net losses widening even as loss per share from continuing operations narrowed compared with the prior year quarter.

MoonLake Immunotherapeutics shares have been volatile, with a 16.08% 30 day share price return and a 7.35% gain over the past week, but a 27.10% decline over 90 days at a last close of US$12.56.

That pattern suggests short term momentum is building again after a weaker quarter for the stock. The 6.89% 1 year total shareholder return contrasts with a much deeper 66.42% total return decline over three years, which still shapes how many investors think about risk and potential upside.

Scan beyond MoonLake Immunotherapeutics and compare this setup with a curated group of biotechs that have strong balance sheets and fundamentals using our list of solid balance sheet and fundamentals (24 results).

MoonLake Immunotherapeutics now trades at a price that sits far below the average analyst estimate, after a sharp 90 day slide followed by a brisk recent rebound. Where might a reasonable fair value range fall within that spread?

Most Popular Narrative: 56% Undervalued

MoonLake Immunotherapeutics closed at $12.56, while the analyst consensus Narrative on Simply Wall St pegs fair value at $28.54 using a 7.52% discount rate. This frames a wide gap for readers to interrogate.

Expected biologics uptake in a large hidradenitis suppurativa population, with management citing about 2.9 million diagnosed and treated patients in the U.S. and only about 3% on biologics, could allow MoonLake Immunotherapeutics to convert a small increase in treated share into meaningful revenue growth if pricing lines up with current HS biologic levels.

See why 1 investors see MoonLake Immunotherapeutics as 56% undervalued.

Result: Fair Value of $28.54 (UNDERVALUED)

Still, insider selling and the risk of dilution from future equity raises could quickly weaken confidence in the MoonLake Immunotherapeutics story if sentiment turns.

Find out about the key risks to this MoonLake Immunotherapeutics narrative.

Next Steps

Mixed about the tone of this MoonLake Immunotherapeutics story so far. Act quickly, review the underlying data on both risk and upside, and weigh the 1 key reward and 3 important warning signs.

Looking for more MoonLake Immunotherapeutics style investment ideas?

If MoonLake Immunotherapeutics has sharpened your focus on risk, reward, and valuation gaps, do not stop here. Broaden your watchlist and give yourself more options before the next move.